Use Of Cyproheptadine Research Articles

Use of cyproheptadine to control urine spraying in a castrated male domestic cat

Use of cyproheptadine to control urine spraying in a castrated male domestic cat

Use of cyproheptadine to control urine spraying and masturbation in a cat

Use of cyproheptadine to control urine spraying and masturbation in a cat

Treatment of the serotonin syndrome with cyproheptadine

The serotonin syndrome is the result of excess stimulation of central nervous 5-hydroxytryptamine (5HT)-1a and 5HT-2 receptors. The diagnosis requires a history of exposure to agents active at serotonin receptors and the presence of alterations in mental status, autonomic instability, and neuromuscular abnormalities such as tremor, hyperreflexia, or myoclonus. In this descriptive case series, five cases of serotonin syndrome are reported. All patients gave a history of recent exposure to one or more serotonergic medications, including moclobemide, paroxetine, sertraline, and venlafaxine, with clinical evidence of serotonin syndrome. All patients were administered cyproheptadine (4–8 mg orally) for serotonergic signs. Three had complete resolution of signs within 2 h of administration. Another two had a residual tremor or hyperreflexia following the first dose, which resolved following a repeat dose. There were no adverse outcomes from cyproheptadine use. The role of specific serotonin receptor antagonists such as cyproheptadine in the treatment of the serotonin syndrome remains to be delineated. Its use should be considered an adjunct to supportive care. Currently, it is unknown whether cyproheptadine modifies patient outcome.

Persistent failure-to-thrive: A case study

The inability to successfully feed a young infant or child is as worrisome to parents as it is to the health care provider. Early growth failures are likely to reflect difficulty with infant homeostasis and often respond to medical management of the physical problem that is temporarily intertering with the infant's ability to feed by mouth. In addition to medical management, however, treatment also necessitates investigation and management of behavioral problems that so universally accompany growth failure. This article presents a case study of a child who presented with poor growth and respiratory symptoms associated with nonregurgitant gastroesophageal reflux, a clinical entity that can be difficult to recognize. Although surgical management of this condition was successful, persistent failure-to-thrive continued and was seemingly recalcitrant to treatment. The use of cyproheptadine as an appetite stimulant to promote weight gain in this child is discussed with a review of the current literature regarding this pharmacologic approach to poor weight gain. A behavioral-based treatment plan is described as an alternate management method, avoiding the use of pharmacologic agents in general.

Successful Treatment of Fluvoxamine-Induced Anorgasmia by Cyproheptadine

We present the first report of the use of cyproheptadine to treat fluvoxamine-induced anorgasmia, in a 63-year-old man suffering from recurrent severe unipolar depression.

Open study on the use of cyproheptadine in hypercortisolemic, unipolar, depressed patients : Enrico G. Camara, M.D. Department of Psychiatry and Psychology, Cleveland Clinic Foundation, Cleveland, OH 44195-5192

Open study on the use of cyproheptadine in hypercortisolemic, unipolar, depressed patients : Enrico G. Camara, M.D. Department of Psychiatry and Psychology, Cleveland Clinic Foundation, Cleveland, OH 44195-5192

The use of cyproheptadine (peritol) as a drug blocking corticotropin secretion in the treatment of Itsenko-Cushing's disease.

1. Treatment of patients with Itsenko-Cushing's disease using inhibitors of steroido-genesis in the adrenals without action on the hypothalamo-pituitary system does not ensure a remission of the disease, which may be due to activation of corticotropin secretion. 2. The joint use of cyproheptadine (peritol) and chloditan leads to a decrease in the basal levels of plasma corticotropin and cortisol, a decrease in the rate of secretion of cortisol, and a normalization of the daily excretion of total 17-HCS, which is manifested in a more prolonged and stable remission in most of the patients. 3. The simultaneous influence of drugs on the elevated secretion of corticotropin and glucocorticoids is a promising method of treatment of Itsenko-Cushing's disease.

Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients.

Plasma levels of growth hormone (GH) and prolactin (PRL) were measured in twelve acromegalic patients after acute administration of an ergoline derivative (methergoline) which has been proposed as a specific serotoninergic blocking agent. The administration of methergoline (4 mg p.o.) was followed by a significant decrease in plasma GH and PRL concentrations. The administration to the same subjects of CB 154 (2.5 mg p.o.), a known stimulator of dopaminergic receptors, led to results almost superimposable to those obtained with methergoline although the suppressive effect of CB 154 on GH and PRL levels was more sustained. Also on the ground of results obtained in these patients with the use of cyproheptadine, phentolamine, or pimozide, we have concluded that methergoline inhibition of GH and PRL release is, in acromegalic patients, most probably due to a dopaminergic mechanism of action.

THE EFFECT OF ANTISEROTONIN AND DEXAMETHASONE IN THE TREATMENT OF RHEUMATOID ARTHRITIS.

SummaryIn order to determine whether antiserotonins might be effective in the treatment of rheumatoid arthritis as suggested by clinical observations and laboratory work with serotonin, two groups of patients were treated differentially with Decadron, Cyproheptadine and Decadron plus Cyproheptadine. This study failed to show any efficacy in the use of Cyproheptadine.